TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8694986

Group type: EXPERIMENTAL
Intervention: Bio-Bright toothbrush
Number of subjects: 28

Group type: COMPARATOR
Intervention: Oral-B 35 toothbrush (Control)
Number of subjects: 28
Study: 2038927

Group type: EXPERIMENTAL
Intervention: Saline (0.05, 0.1, 0.2, 0.3 and 0.5 ml)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Needle insertions using different needle sizes (20 G, 23 G and 30 G)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.75% (0.1 ml, 30 G needle)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (0.1 ml, 30 G needle)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (0.1 ml, 30 G needle)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25% (0.1 ml, 30 G needle)
Number of subjects: 17
Study: 152937

Group type: EXPERIMENTAL
Intervention: 2 liters of fluid intravenously just prior to myelography
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intravenous fluids (control group)
Number of subjects: 100
Study: 31319554

Group type: EXPERIMENTAL
Intervention: Maternal supplementation of 6000 IU/day vitamin D3
Number of subjects: 95

Group type: COMPARATOR
Intervention: Maternal supplementation of 600 IU/day plus infant supplementation of 400 IU/day vitamin D3
Number of subjects: 95
Study: 25453586

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 30U/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Taliglucerase alfa 60U/kg
Number of subjects: 11
Study: 23481298

Group type: EXPERIMENTAL
Intervention: Checkpoints intervention
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 148
Study: 21949036

Group type: EXPERIMENTAL
Intervention: Sanofi‐Aventis branded enoxaparin (SAe) 40 mg subcutaneously once daily for 7 to 10 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: eurofarma‐enoxaparin (Ee) 40 mg subcutaneously once daily for 7 to 10 days
Number of subjects: 200
Study: 19885423

Group type: EXPERIMENTAL
Intervention: Standard edgewise appliances
Number of subjects: 39

Group type: COMPARATOR
Intervention: Straight-wire appliance
Number of subjects: 39
Study: 16717175

Group type: EXPERIMENTAL
Intervention: 15 microg of hemagglutinin
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 30 microg of hemagglutinin
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: 60 microg of hemagglutinin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 16179274

Group type: EXPERIMENTAL
Intervention: VDR TaqI Tt or tt genotype
Number of subjects: 140

Group type: COMPARATOR
Intervention: Regular aerobic exercise
Number of subjects: 140
Study: 12538426

Group type: EXPERIMENTAL
Intervention: Serum from patients with acute coronary syndromes (group 3)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Trolox
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Group 3 serum
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Group 3 (after 1 year)
Number of subjects: 113
Study: 10418767

Group type: EXPERIMENTAL
Intervention: Experimental condition (n = 116) - viewed a video depicting risk factors for sexual assault
Number of subjects: 224

Group type: COMPARATOR
Intervention: Control condition (n = 108) - viewed a video without risk factors for sexual assault
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Follow-up assessment (n = 66)
Number of subjects: 224
Study: 7473485

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) after fasting
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) after feeding
Number of subjects: 14

Group type: COMPARATOR
Intervention: Intravenous methotrexate (MTX)
Number of subjects: 14
Study: 2188774

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oxycodone hydrochloride
Number of subjects: 20
Study: 7023520

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1 plus atropine 0.03 mg kg‐1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 4 mg kg‐1 plus atropine 0.03 mg kg‐1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 4 mg kg‐1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Trimeprazine tartrate 2 mg kg‐1 and 4 mg kg‐1
Number of subjects: 192
Study: 31894037

Group type: EXPERIMENTAL
Intervention: Kuntai capsules (4 capsules per time, 3 times a day)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac sodium enteric‐coated tablets (25mg, 3 times a day)
Number of subjects: 120
Study: 28847895

Group type: EXPERIMENTAL
Intervention: Coronary Artery Calcium (CAC) testing
Number of subjects: 8801

Group type: COMPARATOR
Intervention: Functional Testing (FT)
Number of subjects: 8801

Group type: EXPERIMENTAL
Intervention: Coronary computed tomographic angiography
Number of subjects: 8801
Study: 26738329

Group type: EXPERIMENTAL
Intervention: Shugan Yiyang Capsules combined with sertraline hydrochloride 50 mg qd
Number of subjects: 192

Group type: COMPARATOR
Intervention: sertraline hydrochloride 50 mg qd
Number of subjects: 192
Study: 23361162

Group type: COMPARATOR
Intervention: 0.4 g/kg alcohol (low dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.8 g/kg alcohol (high dose)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Placebo (no alcohol)
Number of subjects: 40
Study: 21401214

Group type: EXPERIMENTAL
Intervention: Cinnarizine 20 mg/dimenhydrinate 40 mg (fixed combination)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Cinnarizine 20 mg (monotherapy)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Dimenhydrinate 40 mg (monotherapy)
Number of subjects: 182
Study: 19059567

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on diet
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on physical exercise
Number of subjects: 1496

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10mg/day) with patient counselling on both diet and physical exercise
Number of subjects: 1496

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1496
Study: 16584288

Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after overnight fasting
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after standard breakfast
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fenofibrate (250 mg sustained-release capsule) after high-fat breakfast
Number of subjects: 24
Study: 14563545

Group type: EXPERIMENTAL
Intervention: Subutex 2 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subutex 8 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subutex 12 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subutex 16 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Suboxone 8 mg/naloxone 2 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Naltrexone 50-150 mg
Number of subjects: 90
Study: 11090789

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg/day for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo for 2 weeks followed by Losartan 50 mg/day for 4 weeks
Number of subjects: 18
Study: 8616130

Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in patients
Number of subjects: 349

Group type: COMPARATOR
Intervention: Chlamydia trachomatis IgG antibodies (titre > or = 1/32) in controls
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: C. pneumoniae antibodies
Number of subjects: 349
Study: 1329697

Group type: EXPERIMENTAL
Intervention: Org 2766 (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (2 mg administered subcutaneously on days 1 and 10 for non-Hodgkin's lymphoma; days 1 and 8 for Hodgkin's disease)
Number of subjects: 28
Study: 6426405

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 2 years (in premenopausal status, after oophorectomy)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Chemotherapy with mitomycin C 20 mg/m2, iv, followed by cyclophosphamide 60 mg/m2, po
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Combination of tamoxifen and chemotherapy
Number of subjects: 422

Group type: COMPARATOR
Intervention: Chemotherapy alone or combination of chemotherapy and tamoxifen
Number of subjects: 422
Study: 29799105

Group type: EXPERIMENTAL
Intervention: Spiritual self-care training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no spiritual self-care training)
Number of subjects: 60
Study: 29674307

Group type: EXPERIMENTAL
Intervention: mHealth interventions (apps)
Number of subjects: 33
Study: 27759092

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 2 treatments per week for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 4 treatments per week for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week for 12 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment (combined groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mild electrical stimulation (MES) with heat shock (HS) treatment, 7 treatments per week
Number of subjects: 60
Study: 24509965

Group type: EXPERIMENTAL
Intervention: ingenol mebutate 0.015% gel
Number of subjects: 329

Group type: COMPARATOR
Intervention: vehicle
Number of subjects: 329
Study: 22744392

Group type: EXPERIMENTAL
Intervention: Treatment for fungal keratitis
Number of subjects: 0
Study: 20233439

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 30
Study: 18394692

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 236
Study: 16140684

Group type: EXPERIMENTAL
Intervention: IBS prevalence in Heilongjiang province (14.02%)
Number of subjects: 5403

Group type: EXPERIMENTAL
Intervention: IBS prevalence in children 12 years and younger (11.86%)
Number of subjects: 5403

Group type: EXPERIMENTAL
Intervention: IBS prevalence in minority students (21.15%)
Number of subjects: 5403

Group type: EXPERIMENTAL
Intervention: Exposure to coldness
Number of subjects: 5403
Study: 12940924

Group type: EXPERIMENTAL
Intervention: Azathioprine or mercaptopurine (MP) treatment
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (patients who tolerated azathioprine or MP)
Number of subjects: 56
Study: 12219878

Group type: EXPERIMENTAL
Intervention: DRSP/E2 + ENA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo + ENA
Number of subjects: 24
Study: 10076125

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with 50 microg gestodene
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 2 mg estradiol combined with 25 microg gestodene
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene (sequentially)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene (continuously)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: 1 mg estradiol combined with 25 microg gestodene
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study: 7488566

Group type: EXPERIMENTAL
Intervention: Elaborate procedural test training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Monetary reinforcement added to test training
Number of subjects: 34
Study: 2274626

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg/day to a maximum of 200 mg/day)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 6167028

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Radiotherapy with bleomycin
Number of subjects: 50
Study: 31895773

Group type: EXPERIMENTAL
Intervention: Flexible health education programs with WeChat Social Messaging platform
Number of subjects: 168

Group type: COMPARATOR
Intervention: Regular prenatal examination and health education programs
Number of subjects: 168
Study: 31791386

Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 498

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 498
Study: 27814453

Group type: EXPERIMENTAL
Intervention: Twice daily fluticasone (F)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Once daily fluticasone plus salmeterol (F + S)
Number of subjects: 493

Group type: EXPERIMENTAL
Intervention: Once daily oral montelukast (M)
Number of subjects: 493
Study: 26464041

Group type: EXPERIMENTAL
Intervention: 60 ml ropivacaine 0.375%
Number of subjects: 56

Group type: COMPARATOR
Intervention: 60 ml isotonic saline
Number of subjects: 56
Study: 25306116

Group type: EXPERIMENTAL
Intervention: Green tea and vitamin C supplements
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22564671

Group type: EXPERIMENTAL
Intervention: Pain signal (colored slide indicating possible pain stimulus)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Safety signal (colored slide indicating no pain stimulus)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Observers with high catastrophizing about others' pain
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Observers with heightened psychopathic traits
Number of subjects: 36
Study: 19304578

Group type: EXPERIMENTAL
Intervention: Larval therapy (bagged larvae, loose larvae)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Hydrogel
Number of subjects: 267
Study: 17436362

Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA) at Siguan points (bilateral LI4 and LR3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 20
Study: 15389896

Group type: EXPERIMENTAL
Intervention: IFN‐beta1a
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 11606914

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg anti-CD11a monoclonal antibody
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study: 9552136

Group type: EXPERIMENTAL
Intervention: Conventional pancreatic enzyme replacement therapy (3 capsules of 8,000 FIP units Creon)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: High-lipase pancreatic enzyme replacement therapy (1 capsule of 25,000 FIP units)
Number of subjects: 11

Group type: COMPARATOR
Intervention: No enzyme intake (control)
Number of subjects: 11
Study: 7844208

Group type: EXPERIMENTAL
Intervention: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.5 mg/day LHRHa during folliculogenesis (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: 0.5 mg/day LHRHa (Decapeptyl) for 14 days followed by 0.1 mg/day LHRHa during folliculogenesis (group B)
Number of subjects: 42
Study: 2897940

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 278

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 278
Study: 29456086

Group type: EXPERIMENTAL
Intervention: Low-Dose Propofol (LDP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard Therapy (ST)
Number of subjects: 66
Study: 27425010

Group type: EXPERIMENTAL
Intervention: Urine C-peptide/creatinine ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stimulated serum C-peptide level
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-dose-adjusted HbA1c level
Number of subjects: 0
Study: 24275953

Group type: EXPERIMENTAL
Intervention: Pretest probability estimates for acute coronary syndrome and pulmonary embolism with suggested clinical actions
Number of subjects: 550

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Intervention group (pretest probability estimates)
Number of subjects: 550
Study: 22712208

Group type: EXPERIMENTAL
Intervention: Brief bright light (BL) exposure on workday mornings
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-BL periods
Number of subjects: 0
Study: 21122661

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (healthy patients)
Number of subjects: 14
Study: 19069579

Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (NRT)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: NRT
Number of subjects: 608
Study: 16152682

Group type: EXPERIMENTAL
Intervention: Intracoronary transplantation of autologous mononuclear bone marrow cells (mBMC) 5-8 days after PCI
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 100
Study: 15117578

Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 2 seconds
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with fine particle size (F) for 4 seconds
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 2 seconds
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhalation of liquid insulin aerosol (1.5 U/kg) with very fine particle size (VF) for 4 seconds
Number of subjects: 13

Group type: COMPARATOR
Intervention: Subcutaneous injection of regular insulin (0.15 U/kg)
Number of subjects: 13
Study: 11054617

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 14500

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 14500

Group type: EXPERIMENTAL
Intervention: Combination of valsartan and captopril
Number of subjects: 14500
Study: 9172021

Group type: EXPERIMENTAL
Intervention: 20 cm2 active patch delivering 50 micrograms/hr of fentanyl and a 30 cm2 placebo patch
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: 30 cm2 active patch delivering 75 micrograms/hr of fentanyl and a 20 cm2 placebo patch
Number of subjects: 62

Group type: COMPARATOR
Intervention: IV PCA with morphine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 62

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 62
Study: 8268649

Group type: EXPERIMENTAL
Intervention: Hemodialysis patients
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CAPD patients
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemodialysis and CAPD patients
Number of subjects: 36
Study: 3709629

Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 3221377

Group type: EXPERIMENTAL
Intervention: Dietary salt restriction (10 g to 2 g salt/day for five days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Salt repletion (2 g salt/day to 20 g/day for five days)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dietary salt restriction
Number of subjects: 25

Group type: COMPARATOR
Intervention: Salt repletion
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dietary salt restriction and salt repletion
Number of subjects: 25
Study: 31784348

Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine and pirfenidone (Group 2)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Prednisone plus azathioprine (Group 1)
Number of subjects: 22
Study: 31385402

Group type: EXPERIMENTAL
Intervention: Bar attachments
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ball attachments
Number of subjects: 40
Study: 28708219

Group type: EXPERIMENTAL
Intervention: 0.1% Cyclosporine A cationic emulsion (CsA CE)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 177
Study: 25728831

Group type: EXPERIMENTAL
Intervention: GSK239512
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 23439604

Group type: EXPERIMENTAL
Intervention: darapladib 40 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: darapladib 80 mg
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: darapladib 160 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 107
Study: 21062330

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea along with zinc, selenium, and vitamin C (EP+)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Echinacea purpurea (EP)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 19320576

Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid drainage (CSF drainage)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No drainage
Number of subjects: 22
Study: 16995871

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil alone (treatment A)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil co-administered with iron (treatment B)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Comparison of treatments A and B
Number of subjects: 16
Study: 12204930

Group type: EXPERIMENTAL
Intervention: Tryptophan-free drink
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 5
Study: 10417497

Group type: EXPERIMENTAL
Intervention: Fexofenadine 80 mg, 120 mg, 180 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Promethazine 30 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 7590484

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Toremifene (60 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31
Study: 2175149

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of Indomethacin and Lisinopril
Number of subjects: 10